470
Participants
Start Date
October 25, 2023
Primary Completion Date
December 30, 2030
Study Completion Date
December 30, 2030
Guardant360
Guardant360 is a qualitative next generation sequencing (NGS)-based in vitro diagnostic device for detection of single nucleotide variants (SNVs), insertions and deletions (indels), copy number amplifications (CNAs), and fusions in genes frequently mutated in cancer, using circulating cell-free DNA (cfDNA) obtained from the plasma of peripheral whole blood collected in Streck Cell-Free DNA Blood Collection Tubes.
RECRUITING
Orchard Healthcare Research Inc., Skokie
Lead Sponsor
Guardant Health, Inc.
INDUSTRY